Related Experiment Video
Updated: Aug 26, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Gefitinib: phase II and III results in advanced non-small cell lung cancer
1University of Colorado Cancer Center, Denver 80262, USA.
Abstract:
Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.
Insights
Gefitinib, an epidermal growth factor receptor inhibitor, shows promise for non-small cell lung cancer. This targeted therapy demonstrated antitumor activity and symptom relief in phase II trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- The epidermal growth factor receptor (EGFR) plays a critical role in tumor progression.
- Targeting EGFR is a key strategy in anticancer drug development.
Purpose of the Study:
- To evaluate the efficacy and tolerability of gefitinib in patients with non-small cell lung cancer (NSCLC).
- To investigate gefitinib as a monotherapy for recurrent NSCLC.
Main Methods:
- Phase II clinical trials were conducted.
- Gefitinib was administered as an oral monotherapy.
Main Results:
- Gefitinib demonstrated clinically meaningful antitumor activity.
- Patients experienced significant symptom relief.
- The drug exhibited a good tolerability profile.
Conclusions:
- Gefitinib is an effective targeted therapy for recurrent non-small cell lung cancer.
- Further clinical trials are warranted to explore additional applications of gefitinib in NSCLC treatment.
